Less volume, more value: how GLP-1 is rewriting the rules of food innovation.

By the Innova Food Tech Corp editorial team · Published September 28, 2026 · Updated September 29, 2026

Editorial note. We updated this article on September 29, 2026. We corrected references and attributions for several studies, updated regulatory information and clarified the scope of some consumption data. We also added direct links to every source. The Spanish edition includes five editorial charts.

In November 2025, Circana reported that households with GLP-1 medication users already accounted for 23% of U.S. households. It also projected that by 2030 they could account for 35% of the food and beverage units sold in the country. The estimate refers to household purchases, not to the share of adults on treatment or to what each person eats. For processors, it raises a concrete innovation question: how to offer portions with nutritional value, good sensory acceptance and the right price for consumers whose needs are changing.

1. The phenomenon in numbers

GLP-1 receptor agonists are medications originally approved for type 2 diabetes. They mimic an intestinal hormone involved in glucose regulation, slow gastric emptying and act on the brain's appetite and satiety signals. Higher doses of some of these molecules were later approved to treat obesity. Two molecules dominate the market. Semaglutide is marketed as Ozempic and Wegovy (Novo Nordisk). Tirzepatide, a dual GIP and GLP-1 receptor agonist, is sold as Mounjaro and Zepbound (Eli Lilly).

In the reference trials, semaglutide 2.4 mg reduced body weight by an average of 14.9% at 68 weeks (STEP 1). Tirzepatide 15 mg reduced it by 20.9% at 72 weeks (SURMOUNT-1). These are different trials, not a direct comparison. That comparison came with SURMOUNT-5: in adults with obesity and without diabetes, tirzepatide achieved a 20.2% reduction versus 13.7% for semaglutide at 72 weeks.

Results in clinical practice are smaller. A Cleveland Clinic study published in Obesity followed 7,881 adults who started either treatment between 2021 and 2023. Average weight loss at one year was 8.7%: 11.9% among those who stayed on treatment and 3.6% among those who stopped within the first three months. The authors attribute the gap mainly to discontinuation and to lower maintenance doses than those used in trials.

Adoption has been rapid. According to a KFF poll conducted in October and November 2025, 12% of U.S. adults take a GLP-1 to lose weight or treat a chronic condition, and 18% have taken one at some point. In the same poll, current use reaches 22% among adults aged 50 to 64. Gallup, surveying in May and June 2026, found that 11% use them specifically for weight loss, up from 3% in 2024. The two polls measure different things: KFF includes any indication, while Gallup counts weight-loss use only.

The financial impact on drugmakers is considerable. Eli Lilly reported 2025 revenue of USD 65.2 billion (+45%), with Mounjaro at USD 22.97 billion (+99%) and Zepbound at USD 13.54 billion (+175%). Novo Nordisk reported to the SEC 2025 sales of DKK 127.1 billion for Ozempic and DKK 79.1 billion for Wegovy. In April 2026, Morgan Stanley projected that the market for type 2 diabetes and obesity treatments could reach USD 190 billion by 2035, more than double the USD 79 billion sold in 2025. It is a projection, not an outcome.

2. What changes in purchasing and consumption

For a processor, the operational question is not how much drugmakers sell. It is what people on treatment buy and stop buying. The available evidence comes from three types of source that should not be mixed: purchase records, self-reported consumption surveys and commercial projections.

Household purchases. According to Circana's November 2025 report, households with GLP-1 users reduced their retail food and beverage spending and increased their restaurant spending. Even so, they still outspend non-user households. They look for products with more protein, fiber and healthy fats, and buy fewer items high in carbohydrates and sugar.

Observed individual purchases. The strongest evidence on actual purchases comes from Denmark. A study published in JAMA Network Open in January 2026 analyzed supermarket receipts from 1,177 people in the SMIL cohort. Of these, 293 started a GLP-1 between 2019 and 2022, and 884 were comparators matched on sex, age and income. After treatment began, users' purchases contained less energy, sugar, carbohydrate and saturated fat per 100 g. They also contained slightly more protein and a smaller share of ultra-processed foods. The comparators did not show this pattern. The authors describe the changes as modest at the individual level, though they could add up at population scale. It is an observational study: it measures purchases, not intake, and shows association, not causation.

Self-reported consumption. A University of Arkansas survey, published in Food Quality and Preference in 2025, interviewed 1,955 people in the U.S. They included 495 current users, 468 former users, 492 potential users and 500 non-users. Current and former users reported eating less of almost every category, especially processed foods, soda, refined grains and beef. Fruit, leafy greens and water were the only categories with a net increase. These are self-reported results, useful for framing hypotheses, not purchase measurements.

Alcohol. Alcoholic beverages are another sensitive category. An analysis published in JAMA Network Open in November 2024 studied 14,053 participants in a telehealth weight-management program. Of the 7,491 who drank at baseline, 45.3% reported drinking less after starting medication. The cohort included several drugs: most were second-generation GLP-1s, but metformin and bupropion/naltrexone were also represented. For that reason the figure is not specific to GLP-1s and cannot be projected directly onto beverage demand.

Purchase intent. An ADM study surveyed users of anti-obesity medications in the U.S., U.K., France, Germany and Spain. Eighty percent said they are willing to pay more for foods and beverages with added health benefits, and 67% said GLP-1-friendly attributes now matter more to them. Seventy-four percent say they feel full sooner, and 73% say portion control matters more than before. This is stated willingness, not price actually paid: it points to an opportunity that must be validated by country, category and price point.

3. Protein, fiber and lean mass

The most useful guide for formulators is the 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. It notes that weight lost on these treatments includes lean mass, which covers muscle and other non-fat tissue, and should therefore not be equated automatically with muscle loss. It proposes protein targets of 1.2 to 1.6 g/kg/day or, as a practical alternative, 80 to 120 g per day. These targets should be individualized and paired with strength training, because protein alone is probably not enough to preserve muscle. The advisory also cautions that using actual body weight in people with obesity can overestimate needs.

For industry, the implication is not to impose a universal dose per product. It is to design portions that are useful within each person's eating pattern. Protein quality matters here as much as quantity: a complete essential amino acid profile, good digestibility and, where relevant, leucine content.

Fiber calls for more care than its popularity suggests. The same advisory addresses the management of gastrointestinal discomfort, which is common with these treatments, and the gradual adaptation of the diet. For someone who already eats little, "more satiety" is not always a benefit. What matters is the type of fiber, the dose, tolerance and how it behaves in the product matrix.

4. How the industry is responding

Major food companies have tried different strategies.

Nestlé announced Vital Pursuit in May 2024, a frozen-meal line aimed at GLP-1 users and weight-conscious consumers, promoted as high in protein, fiber and essential nutrients.

Conagra chose not to reformulate. Starting in January 2025, it added a "GLP-1 Friendly" badge to 26 existing Healthy Choice meals because they are high in protein, low in calories and a good source of fiber. The company said the recipes did not change and that the USDA reviewed and approved the products carrying the badge. That approval covers those labels in the U.S. only: it is not a clinical certification and does not carry over to other markets.

Danone launched Oikos Fusion in August 2025. It is a 7 fl oz cultured dairy drink with 23 g of protein, 5 g of prebiotic fiber and 0 g of added sugar, formulated with a patented blend of whey protein, leucine and vitamin D. Danone said it chose the compact format based on what GLP-1 users asked for: nutrient-dense products that are easy to finish. In March 2026, the company announced a definitive agreement to acquire Huel, a British complete-nutrition brand, to extend its functional nutrition portfolio; the deal remained subject to customary closing conditions.

Our reading is that as protein claims multiply in the market, differentiation is moving elsewhere. What counts is protein quality, its integration with fiber and sugar reduction, and the sensory experience in small portions. These examples illustrate product responses, not universal rules for every category.

5. Latin America: a wave that lands differently

Latin America is not a passive observer, but it should not be read through U.S. data either.

Disease burden. In Mexico, an analysis by the National Institute of Public Health using Ensanut Continua 2020–2023 data estimated adult obesity prevalence at 37.1% (41.0% among women and 33.0% among men). In Brazil, the share of adults with obesity rose from 11.8% in 2006 to 25.7% in 2024, according to the Ministry of Health. The International Diabetes Federation estimates that 16.6 million Brazilian adults aged 20 to 79 were living with diabetes in 2024, of whom 31.9% were undiagnosed. These figures describe a significant disease burden, but they do not equal the number of current or future buyers of products aimed at GLP-1 users.

Access and prices. Brazil shows how quickly access can change. After patent protection for semaglutide ended, the Ministry of Health reported that new brands entering the market cut prices by roughly 70% in less than a year. On September 24, 2026, the Ministry asked Conitec to evaluate adding semaglutide or liraglutide to the public health system (SUS) for obesity. This is an evaluation stage, not implemented coverage. Morgan Stanley identifies Brazil and China as markets that could expand rapidly as generics improve affordability.

Oral options. The FDA approved oral semaglutide 25 mg (the Wegovy pill) in December 2025. On April 1, 2026, it approved Lilly's orforglipron (Foundayo), which can be taken without food or water restrictions. These are U.S. approvals. Their effect in Latin America will depend on local approvals, availability, effective cost and treatment continuity.

Three cautions for anyone designing products for the region:

1. Patterns vary. Consumption patterns differ by country and segment, so findings from the U.S. and Denmark do not transfer automatically.
2. Access depends on household budgets. Until public coverage materializes, access depends on household spending and is concentrated among those who can pay. The price drop in Brazil shows that this profile can change quickly.
3. The "inspired" consumer is a hypothesis. A consumer may emerge who adopts similar patterns (more protein, more fiber, smaller portions) without being on treatment. But that segment must be defined and measured before it is used to project demand.

6. Implications for processors

We propose turning the thesis into a development and validation program, not an inevitable prediction. A processor evaluating this opportunity should come away with concrete project questions:

1. Product objective. Define the consumer, the consumption occasion and the role of the portion: a supplement, a snack and a meal are not the same thing.
2. Nutritional specification. Set protein, fiber and sugar targets justified by category, portion and audience, not a universal number.
3. Technical feasibility. Check taste, viscosity, solubility, heat treatment, sedimentation and stability as they apply to the matrix.
4. Tolerance and use. Test portion size and acceptance with the intended audience, without promising clinical benefits the product has not demonstrated.
5. Economics. Validate cost per portion, acceptable price, margin and repeat purchase, rather than inferring them from intent surveys.
6. Documentation. Keep technical data sheets, lot certificates of analysis, protein quality evidence (PDCAAS or DIAAS, indices that combine amino acid composition and digestibility) and claim substantiation separate.

The Innova journal covers two of these levers in detail: sugar reduction in beverages and protein fortification in dairy beverages.

7. Caveats: what the evidence does not yet resolve

Persistence. In the STEP 1 trial extension, the 327 participants analyzed had lost 17.3% of their body weight on semaglutide. One year after stopping treatment and the lifestyle intervention, they had regained 11.6 percentage points, about two-thirds of the weight lost. In clinical practice, discontinuation is common, as the Cleveland Clinic study cited above shows. And according to Circana, 50% of those who stopped treatment say they are likely to use it again. For commercial analysis, this means distinguishing persistent users, new users and people who interrupt treatment, rather than assuming stable demand.

Surveys versus purchases. Consumption surveys and purchase records measure different things, with different units and biases. Studies based on actual purchases, like the Danish one, tend to show more modest changes than self-reported accounts. The answer is not to average them, but to use each source for what it actually measures.

A moving horizon. Oral options, generics and public coverage decisions could accelerate adoption in some markets and change the user profile. Any commercial plan should be revisited as these factors materialize country by country.

8. Conclusion: from selling more to being worth more

The GLP-1 phenomenon does not destroy food demand. It reconfigures it. The economic unit shifts from how much is consumed to how much value each portion delivers. For processors supplying supermarkets, restaurants and foodservice chains in Latin America, the question is concrete: is the portfolio designed for the consumer who is arriving, or for the one who is leaving? The answer translates into sourcing decisions: which proteins, which fibers, which sweeteners, which stability systems, which grades and which suppliers.

Innova works with food processors across Latin America to adapt formulations and supply chains to this transition. The work is not about swapping one ingredient for another. It is about redesigning the system so that each portion, smaller and more functional, delivers what the label promises and what the consumer is actually looking for, with technical and commercial validation at every step.

This article is a corporate editorial perspective from Innova Food Tech Corp, offered for general informational purposes. It does not constitute medical, regulatory or commercial advice. Figures correspond to the linked sources and their publication dates; market projections are identified as such. Data change quickly and should be checked against the primary source before any decision. Formulation recommendations must be validated case by case against each application's process, packaging and distribution conditions.